Disruption, adaptation and adoption: What does the new face of Clinical Trials look like?
20 August @ 11:00 am - 20 August @ 12:30 pm
The COVID-19 pandemic has rapidly transformed much of the clinical trials and associate medical device, pharmaceutical, and vaccine industries in Australia and internationally.
What’s next for the world of clinical research as we learn to adapt to the changes which are likely to remain with us longer term as a result of the COVID-19 pandemic?
Sponsors, contract research organisations, and sites are now focusing on returning to full business capacity. Changes in practice mean that “business as usual” will be disrupted. Many positive changes will arise – and that’s a significant positive outcome arising from the pandemic.
During this webinar we will hear from sector leaders who will address ethical, practical and clinical implications relating to the new health and safety concerns for patients and employees and learn about their experiences with solutions to those problems, such as telemedicine, direct-to-patient approaches, and implementations of new site level technology to ensure safety measures are properly in place.
- Kylie Sproston, CEO Bellberry Ltd
- Ian Kerridge, PRAXIS Australia, University of Sydney
- Ian Burgess, CEO Medical Technology Association of Australia (MTAA); Non Executive Director of Red Nose
- Liz Wilson, Director, Prime & Partner Site Management ANZ – IQVIA
- Tina Soulis, CEO Neuroscience Trials Australia & Clinical Development Specialist, Strategist, Leader, Networker, Advocate
- Megan Ford, Executive Director, Clinical Trials. Ingham Institute for Applied Medical Research and SWSLHD
- Peter Komocki , Manager, Industry & Regulatory Policy – Medicines Australia
- Dr Rebecca Tunstall, Senior Director Stakeholder Engagement -MTPConnect
- Ben Laverty, Director, Site Management ANZ – IQVIA
- Wendy Keech, CEO Health Translation SA